Fc gamma RIIb affinity enhanced antibody Fc regions

By mutating the Fc region of IgG to enhance FcγRIIB affinity, the shortcomings of agonist antibodies in tumor immunotherapy are addressed, and a significant increase in agonist activity is achieved, making it suitable for the treatment of tumors, inflammatory diseases, and autoimmune diseases.

CN115052888BActive Publication Date: 2026-06-19SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
11 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SHANGHAI JIAOTONG UNIV SCHOOL OF MEDICINE
Filing Date
2020-12-03
Publication Date
2026-06-19

AI Technical Summary

⚠Technical Problem

Existing agonist-type tumor immunotherapy antibodies have not yet been successfully developed, and there are insufficient means to activate the signaling pathways of biological processes with agonist antibodies, making it difficult to effectively enhance the anti-tumor immune response.

⚗Method used

Amino acid mutations in the Fc region of IgG enhance FcγRIIB affinity, optimize antibody agonistic activity, and particularly improve the agonistic activity of agonistic antibodies.

🎯Benefits of technology

It enhances the binding ability of antibodies to FcγRIIB, reduces the binding to activating FcγR, and significantly improves the agonistic activity of agonist antibodies, making it suitable for the treatment of tumors, inflammatory diseases, and autoimmune diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

This invention discloses a modified Fc region having at least one amino acid mutation compared to the parental Fc region. These modified Fc regions exhibit increased affinity for FcγRIIB compared to the parental Fc region. Antibodies, particularly agonist antibodies, incorporating the aforementioned modified Fc region are also disclosed. The modified Fc region of this invention is of significant use in optimizing the agonist activity of antibodies.
Need to check novelty before this filing date? Find Prior Art